Please use this identifier to cite or link to this item:
https://hdl.handle.net/10356/151759
Title: | Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation | Authors: | Chioh, Florence W. J. Fong, Siew-Wai Young, Barnaby Edward Wu, Kan Xing Siau, Anthony Krishnan, Shuba Chan, Yi-Hao Carissimo, Guillaume Teo, Louis L. Y. Gao, Fei Tan, Ru San Zhong, Liang Koh, Angela S. Tan, Seow-Yen Tambyah, Paul A. Renia, Laurent Ng, Lisa F. P. Lye, David C. Cheung, Christine |
Keywords: | Science::Medicine | Issue Date: | 2021 | Source: | Chioh, F. W. J., Fong, S., Young, B. E., Wu, K. X., Siau, A., Krishnan, S., Chan, Y., Carissimo, G., Teo, L. L. Y., Gao, F., Tan, R. S., Zhong, L., Koh, A. S., Tan, S., Tambyah, P. A., Renia, L., Ng, L. F. P., Lye, D. C. & Cheung, C. (2021). Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation. ELife, 10, e64909-. https://dx.doi.org/10.7554/eLife.64909 | Project: | COVID19RF-001 COVID19RF-060 H20/04/g1/006 NRF2017_SISFP09 MOE2018-T2-1-042 H18/01/a0/017 |
Journal: | eLife | Abstract: | Numerous reports of vascular events after an initial recovery from COVID-19 form our impetus to investigate the impact of COVID-19 on vascular health of recovered patients. We found elevated levels of circulating endothelial cells (CECs), a biomarker of vascular injury, in COVID-19 convalescents compared to healthy controls. In particular, those with pre-existing conditions (e.g., hypertension, diabetes) had more pronounced endothelial activation hallmarks than non-COVID-19 patients with matched cardiovascular risk. Several proinflammatory and activated T lymphocyte-associated cytokines sustained from acute infection to recovery phase, which correlated positively with CEC measures, implicating cytokine-driven endothelial dysfunction. Notably, we found higher frequency of effector T cells in our COVID-19 convalescents compared to healthy controls. The activation markers detected on CECs mapped to counter receptors found primarily on cytotoxic CD8+ T cells, raising the possibility of cytotoxic effector cells targeting activated endothelial cells. Clinical trials in preventive therapy for post-COVID-19 vascular complications may be needed. | URI: | https://hdl.handle.net/10356/151759 | ISSN: | 2050-084X | DOI: | 10.7554/eLife.64909 | Rights: | © 2021, Chioh et al. This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited. | Fulltext Permission: | open | Fulltext Availability: | With Fulltext |
Appears in Collections: | LKCMedicine Journal Articles |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
elife-64909-v1.pdf | 3.22 MB | Adobe PDF | View/Open |
Page view(s)
150
Updated on May 17, 2022
Download(s) 50
23
Updated on May 17, 2022
Google ScholarTM
Check
Altmetric
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.